Home > Boards > US Listed > Biotechs > Aravive - Oncology/Biotech Company (ARAV)

The only thing I can figure out is

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
cjstocksup Member Profile
Member Level 
Followed By 3,644
Posts 234,639
Boards Moderated 1
Alias Born 07/30/07
160x600 placeholder
Aravive EPS beats by $0.01, misses on revenue Seeking Alpha - 5/6/2021 7:26:21 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 5/6/2021 7:15:18 AM
Aravive Reports First Quarter 2021 Financial Results and Announces Plans to Investigate AVB-500 in Clinical Trial as First-L... GlobeNewswire Inc. - 5/6/2021 7:00:00 AM
Aravive shares rise after dosing first patient in late-stage ovarian cancer study Seeking Alpha - 4/27/2021 10:54:45 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 4/27/2021 7:11:36 AM
Aravive Announces First Patient Dosed in Phase 3 Registrational Trial Evaluating AVB-500 in Patients with Platinum Resistant... GlobeNewswire Inc. - 4/27/2021 7:00:00 AM
Amended Statement of Beneficial Ownership (sc 13d/a) Edgar (US Regulatory) - 4/15/2021 7:45:28 AM
Sec Staff Action/letter (sec Staff) Edgar (US Regulatory) - 3/24/2021 12:34:58 PM
Sec Staff Action/letter (sec Staff) Edgar (US Regulatory) - 3/24/2021 12:33:36 PM
Amended Statement of Beneficial Ownership (sc 13d/a) Edgar (US Regulatory) - 3/23/2021 7:06:44 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 3/22/2021 7:13:50 PM
Clovis Oncology, Marker Therapeutics leads healthcare gainers; Idera Pharmaceuticals, Praxis Precision Medicines among major ... Seeking Alpha - 3/19/2021 11:04:17 AM
Securities Registration: Employee Benefit Plan (s-8) Edgar (US Regulatory) - 3/17/2021 4:07:28 PM
Aravive shares rise on Q4 results, pipeline updates Seeking Alpha - 3/16/2021 10:18:25 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 3/16/2021 7:16:07 AM
Annual Report (10-k) Edgar (US Regulatory) - 3/16/2021 7:11:57 AM
Aravive EPS beats by $0.27, beats on revenue Seeking Alpha - 3/16/2021 7:06:56 AM
Aravive Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Updates GlobeNewswire Inc. - 3/16/2021 7:00:00 AM
Aravive to Present Phase 1b Data Evaluating AVB-500 in Platinum Resistant Ovarian Cancer at 2021 Society of Gynecologic Oncol... GlobeNewswire Inc. - 3/12/2021 7:00:00 AM
Aravive shares rise 8% as BTIG initiates with a buy Seeking Alpha - 3/8/2021 10:28:42 AM
Aravive starts dosing in Phase 1b/2 AVB-500 cancer study Seeking Alpha - 3/8/2021 8:06:08 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 3/8/2021 7:05:50 AM
Aravive Announces First Patient Dosed in Phase 1b/2 Clinical Trial of AVB-500 in Patients with Clear Cell Renal Cell Carcino... GlobeNewswire Inc. - 3/8/2021 7:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 3/2/2021 8:01:42 AM
Aravive to Participate in Upcoming Virtual Investor Conferences in March GlobeNewswire Inc. - 3/2/2021 7:00:00 AM
cjstocksup Member Level  Wednesday, 11/20/19 11:56:18 PM
Re: [SMART MONEY] post# 28
Post # of 51 
The only thing I can figure out is how day trading ruins so many good news pharma plays because they buy and sell in minutes on any red. They killed it today. I liked the upgrades. I love the news and low float. Hopefully they can get it moving up again ahead of more news then it should break that $30.00 during market hours. I think the other poster who talked about a buyout at about $45.00 base on his DD is also likely ahead. Bottom line it was so easy to make money pre market to $29.00. I noticed the problem was when it started to drop even late pre market it did not recover either.
Quote:
was only fun if you made money.... most didnt

VWAP 11.38

closed under $10 reg & ah sessions



Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences